A new study examined more than 5100 adults with nonvalvular AF who were starting oral anticoagulation therapy. Patients were divided into 4 groups, each with different baseline clinical ...

In my practice, I’ve used all the NOAC (novel anticoagulant) therapies available for stroke prevention in my nonvalvular atrial fibrillation patients. I have used dabigatran in my nonvalvular atrial ...

Please provide your email address to receive an email when new articles are posted on . Label-concordant dosing may benefit patients on dialysis with nonvalvular atrial fibrillation more than ...

The association between frailty and clinical outcomes in older adults with NVAF hasn’t been thoroughly examined in real-world settings. New data finds frailty to be associated with cardiovascular and ...

Each month, The Clinical Advisor makes one new clinical feature available ahead of print. Don’t forget to take the poll. The results will be published in the next month’s issue. The American Heart ...

RARITAN, NJ, Janssen Pharmaceuticals, Inc. announced today the U.S. Food and Drug Administration (FDA) has approved XARELTO® to reduce the risk of stroke and systemic embolism in patients with ...

Expert Rev Cardiovasc Ther. 2012;10(4):433-439. Another important trial that needs discussion is the ROCKET AF trial. ROCKET AF studied 14,264 patients with nonvalvular AF and compared the Factor Xa ...

Retrospective data support use of oral anticoagulants for death and MACE risk reduction in patients with end-stage kidney disease and nonvalvular atrial fibrillation who have an elevated CHA2DS2-VASc ...

The ratio of early transmitral flow velocity (E) to early diastolic mitral annular velocity (E') is a novel index of left ventricular filling pressure and has been shown to predict prognosis in ...

Dabigatran and rivaroxaban were associated with lower risks of adverse renal outcomes compared with warfarin. Atrial fibrillation (AFib) patients taking non-vitamin K antagonist oral anticoagulants ...

In 2017, we have the advantage of, having available to us, 4 large clinical trials. All of the phase IV studies that have been published over the last few years review the use of novel oral ...